We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Futura Medical
MED3000: more detail on FM57 resultsFutura Medical
Encouraging FY19 results and MED3000 updateMaxCyte
Top cancer Advanced Therapy Company partnershipBonesupport
Accelerated FDA pathway for CERAMENT GHutchison China MediTech
Progress suggests that 2020 will be a decisive yearNexstim
Focussing on strategic prioritiesBonesupport
Cementing the foundations for growthHutchison China MediTech
A wealth of opportunity for surufatinibFutura Medical
MED3000 European regulatory pathway is clearerBerGenBio
Focused on second-line NSCLC and AML